Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › HDM1002

HDM1002

GLP-1 (small molecule) · oral · Huadong Medicine

Data cut 12 November 2026 · page built 16 November 2026 · 2 trial arms · 1 trials with results · 3 registered trials · see on the pipeline board

Summary

Also known as
Zhongmei Huadong
Mechanism
GLP-1 (small molecule)
Route
oral
Company
Huadong Medicine
Highest development stage
phase 3
Status (as of data cut)
Phase 3 HDM1002-301 positive (oral; up to −12.2 % efficacy estimand at 52 weeks); pre-NDA verify
Next milestone
NDA in China

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 HDM1002-301 (oral)Huadong announcement (Sep 2026)
T2D2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HDM1002-301200 mg QDobesity china52857−10.7 % vs −1.5 %
Δ −9.2 pp
−9.4 % vs −1.5 %
Δ −7.9 pp
—1.5 vs 0.6—————press release
HDM1002-301400 mg QDobesity china52857−12.2 % vs −1.5 %
Δ −10.7 pp
−11.3 % vs −1.5 %
Δ −9.8 pp
—2.0 vs 0.6—————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (6)
  • 200 mg QD · weight_eff · HKEX filing
    第 52 周 -10.7% -12.2% -1.2%
  • 200 mg QD · weight_tp · HKEX filing
    第 52 周 -9.4% -11.3% -0.9%
  • 200 mg QD · ae_dc · 四、安全性 paragraph
    因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)
  • 400 mg QD · weight_eff · HKEX filing
    第 52 周 -10.7% -12.2% -1.2%
  • 400 mg QD · weight_tp · HKEX filing
    第 52 周 -9.4% -11.3% -0.9%
  • 400 mg QD · ae_dc · 四、安全性 paragraph
    因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)

Registered trials (3)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07193459
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
T2DPhase 3recruiting2025-08 → 2026-10360recruitingNCT07193459
NCT07082114
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
T2DPhase 3recruiting2025-07 → 2027-02800recruitingNCT07082114
NCT06885021 · China
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
ObesityPhase 3not yet recruiting2025-03 → 2026-05780not yet recruitingNCT06885021

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HDM1002. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/hdm1002/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.